Lv5
950 积分 2023-11-05 加入
不喜欢科研的科研狗呀
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
9个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
9个月前
已完结
Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma
9个月前
已关闭
皖公网安备34019202002308
